LY-2562175
LY-2562175 Basic information
- Product Name:
- LY-2562175
- Synonyms:
-
- LY-2562175
- CS-2847
- 1H-Indole-3-carboxylic acid, 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy]-1-piperidinyl]-1-methyl-
- LY 2562175,NR1H4,Inhibitor,LY-2562175,Autophagy,LY2562175,inhibit,FXR
- 6-(4-((5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid
- LY2562175, 10 mM in DMSO
- TERN-101
- CAS:
- 1103500-20-4
- MF:
- C28H27Cl2N3O4
- MW:
- 540.44
- Mol File:
- 1103500-20-4.mol
LY-2562175 Chemical Properties
- Boiling point:
- 740.1±60.0 °C(Predicted)
- Density
- 1.48±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMF: 20 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml
- form
- A crystalline solid
- pka
- 3.43±0.10(Predicted)
- color
- White to light yellow
LY-2562175 Usage And Synthesis
Description
LY2562175 is a farnesoid X receptor (FXR) agonist (EC50 = 193 nM in a reporter assay). It is selective for FXR over the glucocorticoid, androgen, mineralocorticoid, and progesterone receptors in HEK293 cells overexpressing the human receptors (EC50s = >10 μM for all in a radioligand binding assay). LY2562175 increases the interaction between FXR and steroid receptor coactivator 1 (SRC-1) with an EC50 value of 121 nM in a cell-free assay. It reduces plasma triglyceride and total cholesterol levels in LDL receptor-null mice (ED50s = 3.4 and 2 mg/kg, respectively). LY2562175 also decreases plasma LDL and increases HDL levels in Zucker diabetic fatty (ZDF) rats when administered at doses of 3, 10, and 30 mg/kg for nine days.
Uses
LY2562175, is a potent and selective FXR agonist with an EC50 of 193 nM.
in vivo
LY2562175 causes a dose-dependent decrease in serum cholesterol and serum triglycerides. At a dose of 10 mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from control group. The ED50 for serum cholesterol is determined to be 2 and 3.4 mg/kg for serum triglycerides. Treatment of female ZDF rats with LY2562175 results in a dose dependent lowering of plasma triglycerides in the fasted and nonfasted states. When administered as a fixed dose combination with BRL49653, LY2562175 further lowers fasted and nonfasted plasma triglycerides. FPLC fractionation of the lipoproteins reveals that LY2562175 treatment results in a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model[1].
LY-2562175Supplier
- Tel
- 0755-0755-66853366 13670046396
- sales@chem-strong.com
- Tel
- 021-52996696，15000506266 15000506266
- Tel
- 021-61350663 13052117465
- sales@zehanbiopharma.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 17754423994 17754423994
- 2853530910@QQ.com
LY-2562175(1103500-20-4)Related Product Information
- LY 294002 Hydrochloride
- LY-2940094
- LY2828360
- LY2228820
- Etalocib
- 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol
- LY3214996
- LY2584702
- LY 2784544
- LY2409881 trihydrochloride
- LY-364947
- LY 88074
- (S)-3-fluoro-4-(4-((2-(3-fluorophenyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide
- Cyclo[Phe-Tyr-Lys(iPr)-D-Arg-2-Nal-Gly-D-Glu]-Lys(iPr)-NH2